User:Mr. Ibrahem/Necitumumab

Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC). Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread. Such use; however, is not recommended in the United Kingdom. It is given by gradual injection into a vein.

Common side effects include rash and low magnesium. Other side effects may include cardiac arrest and blood clots. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).

Necitumumab was approved for medical use in the United States in 2015. While it was approved for use in Europe in 2016, this approval was subsequently withdrawn. In the United Kingdom it cost the NHS £1,450 per dose as of 2021. This amount in the United States costs about 4,500 USD.